NCT03333265View on ClinicalTrials.gov

Primary Chemoprevention of Familial Adenomatous Polyposis With Berberine Hydrochloride

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

September 1, 2017

Primary Completion Date

August 31, 2020

Study Completion Date

June 1, 2021

Conditions
Colorectal Adenomas
Interventions
DRUG

100mg Berberine hydrochloride

patients take the Berberine hydrochloride 100mg tablet by mouth, 2 times a day with 6 months

DRUG

300mg Berberine hydrochloride

patients take the Berberine hydrochloride 300mg tablet by mouth, 2 times a day with 6 months

DRUG

Placebo Oral Tablet

patients take mmic Berberine hydrochloride tablet by mouth, 2 times a day with 6 months

Trial Locations (1)

710000

Li, Xi'an

All Listed Sponsors
lead

Xijing Hospital of Digestive Diseases

OTHER

NCT03333265 - Primary Chemoprevention of Familial Adenomatous Polyposis With Berberine Hydrochloride | Biotech Hunter | Biotech Hunter